WuXi Biologics Wins 2021 CMO Leadership Awards in All Six Core Categories prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Pharmaceutical Contract Development and Manufacturing Market Worth $126 6 Billion by 2024 sandiegosun.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from sandiegosun.com Daily Mail and Mail on Sunday newspapers.
Cannabis Mergers and Acquisitions Are Heating Up, With More Than $600 Million in Deals Announced Last Tuesday Alone and That’s on Top of Additional Transactions Unveiled Since the 2020 U.S. Election Last Month
New York-based Multi-State Operator (MSO) Columbia Care (CSE:CCHW) (OTCQX:CCHWF) (FSE: 3LP) announced Tuesday it reached a deal to acquire privately-held Green Leaf Medical for $240 million, expanding its presence in the Mid-Atlantic. Ayr Strategies (CSE:AYR) (OTCQX:AYRSF), of New York and Toronto, announced a $290 million all-stock acquisition of Florida-based Liberty Health (CSE:LHS) (OTCQX:LHSIF) (FRA: S6UQ and a $101 million acquisition of a licensed New Jersey MMJ operator with three dispensaries. On top of that, on December 16, leading Canadian Licensed-Producers (LPs) Aphria (TSX:APHA) (NYSE:APHA) (FRA: 10E) and Tilray (NASDAQ:TLRY) (FRA: 2HQ) announced plans to merge in a deal that would create the world’s largest cannabis operator based on pro-for
NationofChange
UK regulators give okay to use psychedelic drug to treat depression in first clinical trial We think this could be a treatment for a number of depressive disorders besides major depression, including PTSD, treatment-resistant depression, obsessive-compulsive disorder, and possibly some types of substance abuse.
Dimethyltriptamine, a psychedelic drug, will soon be trial-led in the United Kingdom to treat depression. UK Regulators will begin the trial by giving the “spirit molecule” drug to healthy individuals and then follow it up with a second trial on patients suffering from depression.
The drug is known for inducing “powerful hallucinogenic trips” and it will be paired with psychotherapy, The Guardian reported.